10-QPeriod: Q2 FY2015

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2015

Filed July 30, 2015For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported solid revenue growth for the six months ended June 30, 2015, with total revenue increasing by 6.1% year-over-year to $795.8 million. This growth was primarily driven by the Companion Animal Group (CAG) segment, which saw an 8.9% increase in revenue, particularly in recurring diagnostics revenue. The company successfully transitioned to an all-direct sales strategy in the U.S., which is contributing to distributor margin capture and influencing revenue growth. Despite a challenging foreign currency environment impacting international revenue, IDEXX demonstrated resilience. Financially, the company maintained profitability, with net income attributable to IDEXX stockholders at $103.5 million for the first six months. The balance sheet shows a significant increase in long-term debt, reflecting recent note issuances to fund general corporate purposes. While cash flow from operations decreased compared to the prior year, primarily due to changes in working capital, the company maintained sufficient liquidity through its credit facility and cash reserves.

Financial Highlights

54 data points
Beta

Revenue

$413.34M

56.3% Gross Margin

Net Income

$56.91M

13.8% Net Margin

EPS (Diluted)

$0.60

Total Assets

$1.48B

Cash & Equivalents

$163.15M

Free Cash Flow

$56.31M

Financial Statements
Beta
Revenue$413.34M
Cost of Revenue$180.59M
Gross Profit$232.76M
R&D Expenses$24.32M
Operating Income$88.30M
Interest Expense$7.26M
Net Income$56.91M
EPS (Basic)$0.61
EPS (Diluted)$0.60
Shares Outstanding (Basic)93.38M
Shares Outstanding (Diluted)94.31M

Key Highlights

  • 1Total revenue increased by 6.1% to $795.8 million for the six months ended June 30, 2015, compared to the same period in 2014.
  • 2Companion Animal Group (CAG) was the primary growth driver, with revenue up 8.9% to $676.1 million, largely due to recurring diagnostics revenue.
  • 3The company successfully completed the transition to an all-direct sales strategy in the U.S., which is contributing to revenue growth through distributor margin capture.
  • 4Net income attributable to stockholders was $103.5 million for the first six months of 2015.
  • 5Long-term debt increased significantly due to the issuance of new senior notes, totaling approximately $250 million during the period.
  • 6Cash flow from operating activities decreased by $49.8 million to $65.5 million for the six months ended June 30, 2015, impacted by changes in working capital.
  • 7The company reported $163.2 million in cash and cash equivalents as of June 30, 2015, and had $201.0 million in remaining borrowing availability under its credit facility.

Frequently Asked Questions

The transition to an all-direct sales strategy in the U.S. by January 1, 2015, has allowed IDEXX to capture distributor margins, contributing to revenue growth. It also influences working capital by increasing accounts receivable and inventory carrying costs.

The strengthening of the U.S. dollar negatively impacted international revenue, decreasing it by approximately $25.6 million in the three-month period and $46.9 million in the six-month period ended June 30, 2015. However, foreign currency hedging activities partially offset these adverse effects.

As of June 30, 2015, IDEXX had $163.2 million in cash and cash equivalents and $180.9 million in marketable securities. The company also had $201.0 million of available borrowing capacity under its $700 million credit facility, indicating a strong liquidity position.

The company issued approximately $250 million of senior notes through private placements in the first half of 2015. These funds were used for general corporate purposes, including repaying amounts outstanding under its revolving credit facility.